Brokerages Set Surmodics, Inc. (NASDAQ:SRDX) Target Price at $43.00
Groupe la Francaise Sells 33,700 Shares of Surmodics, Inc. $SRDX
Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today
Federal Judge Clears Path For GTCR's Takeover Of Surmodics After FTC Challenge
Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR
Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations
Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3
SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts
SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
SurModics (SRDX) Q3 Earnings and Revenues Beat Estimates
Surmodics (SRDX) Q3 EPS Turns Positive
Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance
Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts
SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say
SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance
Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System
Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries
Here's Why You Should Retain Surmodics Stock in Your Portfolio Now
SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR
FTC sues to block private equity firm's deal to buy medical device coatings maker Surmodics
SurModics (SRDX) Loses -13.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries
Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up
Compared to Estimates, SurModics (SRDX) Q1 Earnings: A Look at Key Metrics
SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates
Here's Why You Should Add Surmodics Stock to Your Portfolio Now
After Plunging -10.42% in 4 Weeks, Here's Why the Trend Might Reverse for SurModics (SRDX)
SurModics (SRDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Best Momentum Stocks to Buy for January 3rd
New Strong Buy Stocks for January 3rd
Why Is SurModics (SRDX) Up 4% Since Last Earnings Report?
SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System
SRDX Stock Down Despite FDA Clearance for Pounce XL System
SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround
SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Here's What Key Metrics Tell Us About SurModics (SRDX) Q3 Earnings
SurModics (SRDX) Reports Q3 Loss, Tops Revenue Estimates
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. – SRDX
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger of Surmodics, Inc. - SRDX
Surmodics (SRDX) Inks Group Purchasing Agreement With Premier